

VA/DoD CLINICAL PRACTICE GUIDELINE FOR THE DIAGNOSIS AND MANAGEMENT OF HYPERTENSION IN THE PRIMARY CARE SETTING

**Department of Veterans Affairs
Department of Defense**

Clinician Guideline Summary

QUALIFYING STATEMENTS

The Department of Veterans Affairs and the Department of Defense guidelines are based upon the best information available at the time of publication. They are designed to provide information and assist decision-making. They are not intended to define a standard of care and should not be construed as one. Neither should they be interpreted as prescribing an exclusive course of management.

This Clinical Practice Guideline is based on a systematic review of both clinical and epidemiological evidence. Developed by a panel of multidisciplinary experts, it provides a clear explanation of the logical relationships between various care options and health outcomes while rating both the quality of the evidence and the strength of the recommendations.

Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional making use of these guidelines is responsible for evaluating the appropriateness of applying them in the setting of any particular clinical situation.

These guidelines are not intended to represent TRICARE policy. Further, inclusion of recommendations for specific testing and/or therapeutic interventions within these guidelines does not guarantee coverage of civilian sector care. Additional information on current TRICARE benefits may be found at www.tricare.mil or by contacting your regional TRICARE Managed Care Support Contractor.

Version 1.0 – 2014

Summary

In the United States (US), about 77.9 million adults (one out of every three) have hypertension. Of those only 81.5% are aware of their condition, 74.9% are undergoing treatment, and just over half (52.5%) have their hypertension controlled. [1] Uncontrolled hypertension has been shown to be higher in older Americans, non-Hispanic blacks and individuals with certain co-morbid conditions, including diabetes and chronic kidney disease (CKD). [2]

In a 2008 study, it was found that 13% of active duty Service Members had hypertension, the majority of which were <40 years of age. [3] It was reported that, as in the civilian population, increased age, increased body mass index (BMI), male sex, black race/ethnicity, and senior rank were all independently associated with hypertension. Over 37% of Veterans have hypertension, making it the most common chronic medical condition among Veterans. [4] The control of hypertension, however, has significantly improved among Veterans. While only 45.7% of Veterans had their blood pressure controlled in 2000, by 2010, the rate had improved to 76.3%. [5]

Hypertension is clinically defined as a systolic blood pressure (SBP) ≥ 140 mmHg or a diastolic blood pressure (DBP) of ≥ 90 mmHg. Prehypertension is classified as SBP 120-139 or DBP 80-89. Hypertension is usually asymptomatic; therefore, routine screening is important in order to diagnosis the condition. Also, because patients will mostly not feel sick, the asymptomatic nature of hypertension can lead to challenges with adherence to treatment.

Complications of hypertension include damage to the large arteries (macrovascular complications) that can lead to stroke, myocardial infarction (MI), or peripheral arterial diseases, as well as damage to the smaller arteries (microvascular complications) that can lead to CKD or retinopathy. In addition to these arterial complications, hypertension by itself can lead to left ventricular hypertrophy (LVH) and congestive heart failure (CHF), another frequent cause of death in the US.

The Department of Veterans Affairs (VA) and the Department of Defense (DoD) Clinical Practice Guideline (CPG) for the Diagnosis and Management of Hypertension in the Primary Care Setting is intended to assist healthcare providers in all aspects of outpatient care for patients with hypertension. The system-wide goal of evidence-based guidelines is to improve the patient's health and wellbeing. The overall expected outcome of successful implementation of this guideline is to:

- Formulate an efficient and effective assessment of the patient's condition
- Optimize the use of therapy to reduce symptoms and enhance functionality
- Minimize preventable complications and morbidity
- Emphasize the use of personalized, proactive, patient-driven care

This CPG addresses various management strategies for patients with hypertension (HTN). This includes assessing the benefits and harms associated with antihypertensive pharmacologic therapies as well as the blood pressure thresholds to initiate therapy and appropriate blood pressure targets. In addition to primary care provider pharmacological management strategies, the CPG discusses the impact of non-pharmacologic therapies (e.g., weight reduction, sodium reduction, physical activity) on improving

hypertension management. The CPG also reviews what measurement techniques are the best indicators to initiate hypertension therapy.

Strength of Recommendations

This CPG uses the GRADE methodology to assess the quality of the evidence base and assign a grade for the strength for each recommendation. The GRADE system uses the following four domains to assess the strength of each recommendation: [6]

- Balance of desirable and undesirable outcomes
- Confidence in the quality of the evidence
- Values and preferences
- Other implications, as appropriate, e.g.,:
 - Resource Use
 - Equity
 - Acceptability
 - Feasibility
 - Subgroup considerations

The framework below was used by the VA/DoD HTN Work Group to guide discussions on each domain.

Table 1. Evidence to Recommendation Framework

Decision Domain	Judgment
Balance of desirable and undesirable outcomes	
Given the best estimate of typical values and preferences, are you confident that the benefits outweigh the harms and burden or vice versa? Are the desirable anticipated effects large? Are the undesirable anticipated effects small? Are the desirable effects large relative to undesirable effects?	Benefits outweigh harms/burden Benefits slightly outweigh harms/burden Benefits and harms/burden are balanced Harms/burden slightly outweigh benefits Harms/burden outweigh benefits
Confidence in the quality of the evidence	
Is there high or moderate quality evidence that answers this question? What is the overall certainty of this evidence?	High Moderate Low Very low
Values and preferences	
Are you confident about the typical values and preferences and are they similar across the target population? What are the patient’s values and preferences? Are the assumed or identified relative values similar across the target population?	Similar values Some variation Large variation
Other implications (e.g., resource use, equity, acceptability, feasibility, subgroup considerations):	
Are the resources worth the expected net benefit from the recommendation? What are the costs per resource unit? Is this intervention generally available?	Various considerations

Decision Domain	Judgment
Is this intervention and its effects worth withdrawing or not allocating resources from other interventions? Is there lots of variability in resource requirements across settings?	

The strength of a recommendation is defined as the extent to which one can be confident that the desirable effects of an intervention outweigh its undesirable effects, and is based on the framework above, which combines the four domains. [6]

The GRADE of a recommendation is based on the following elements:

- Four decision domains used to determine the strength and direction (described above)
- Relative strength (Strong or Weak)
- Direction (For or Against)

The relative strength of the recommendation is based on a binary scale, “Strong” or “Weak.” A strong recommendation indicates that the Work Group is highly confident that desirable outcomes outweigh undesirable outcomes. If the Work Group is less confident of the balance between desirable and undesirable outcomes, they present a weak recommendation.


Similarly, a recommendation for a therapy or preventive measure indicates that the desirable consequences outweigh the undesirable consequences. A recommendation against a therapy or preventive measure indicates that the undesirable consequences outweigh the desirable consequences.

Using these elements, the grade of each recommendation is presented as part of a continuum:

- Strong For (or “We recommend offering this option ...”)
- Weak For (or “We suggest offering this option ...”)
- Weak Against (or “We suggest not offering this option ...”)
- Strong Against (or “We recommend against offering this option ...”)

Algorithm

Screening and Diagnosis Module A



Sidebar A: Classification

	SBP (mmHg)	DBP (mmHg)
Normal:	< 120	and < 80
Prehypertension*:	120-139	and/or 80-89
Hypertension:	≥140	or ≥90

*But not ≥140mmg SBP or ≥ 90mm Hg DBP

Sidebar B: Confirm Diagnosis

Confirm clinical BP within 1-4 weeks.

If the follow-up BP value is ≥ 140 mmHg SBP or ≥ 90 mmHg DBP, make diagnosis without further testing.

If the follow-up BP value is within prehypertensive range or provider/ patient is uncertain about diagnosis, consider performing HBPM or 24-hour ABPM.

Diagnose hypertension if:
 HBPM: SBP ≥ 135 mmHg or DBP ≥ 85 mmHg
 24-hour ABPM: SBP ≥ 130 or DBP ≥ 80 mmHg


If HBP or ABP is less than the values above, consider diagnosing as prehypertension or white coat hypertension depending on blood pressure reading (see sidebar A).

- Sidebar C: Recommended Lab Tests**
- Urinalysis; consider an albumin to creatinine ratio test if urinalysis is positive for protein
 - Basic metabolic panel
 - Non-fasting lipid profile
 - 12-lead electrocardiogram
 - Hematocrit and calcium (optional)

ABBREVIATIONS:

ABP = ambulatory blood pressure; ABPM = ambulatory blood pressure monitoring; ACEI= angiotensin-converting enzyme inhibitor; ARB= angiotensin II receptor blockers; BP= blood pressure; CKD= chronic kidney disease; CV = cardiovascular; DBP = diastolic blood pressure; DHP CCB= dihydropyridine calcium channel blocker; HBP = home blood pressure; HBPM = home blood pressure monitoring; HTN= hypertension; LSM= lifestyle modification; RFs = risk factors; SBP = systolic blood pressure; SDM= shared decision making; TOD= target organ damage

Management Module B



Sidebar D: Goals for Blood Pressure

Without diabetes: <150/90 mm Hg
 With diabetes: <150/85 mm Hg
 *<140/85 mm Hg

*Suggested for patients with diabetes who tolerate the antihypertensive medications necessary to reach this goal.

Sidebar E: Initiate Drug Therapy

General Population (including patients with coronary disease, prior MI, or diabetes):

1st Line: Thiazide-type diuretics
 2nd Line: ACEIs, ARBs, or long-acting DHP CCBs

Additional drug classes may be added as needed to reach BP goal. (Refer to Table 4)

Specific Populations:

- For patients with **CKD**, recommend ACEIs or ARBs as 1st line therapy.
- For **African American** patients, recommend **not** using ACEIs or ARBs as monotherapy.
- For **African American patients with CKD**, suggest combining a thiazide-type diuretic with an ACEI or ARB.

Sidebar F: Optimize Treatment

- Optimize treatment (Refer to Table 4)
 - Titrate initial drug
 - Add another agent from a different class
- Assess adherence
- Reevaluate diagnosis (resistant HTN)
- Consider evaluation for interfering substances or contributing secondary causes of hypertension
- Consider specialty consultation for patients with resistant hypertension

Table 2. Evidence-Based Clinical Practice Recommendations for the Clinical Practice Guideline for the Diagnosis and Management of Hypertension in the Primary Care Setting

Recommendation	Strength of Recommendation
Screening, Diagnosis and Measurement of Hypertension	
<i>Screening</i>	
1. We recommend screening adults for elevated blood pressure occur periodically, preferably annually. <i>(Modified from 2004 VA/DoD HTN CPG without an updated systematic review of the evidence.)</i>	Strong for
2. We suggest that screening occur at the time of routine preventive care or routine health assessment. <i>(Modified from 2004 VA/DoD HTN CPG without an updated systematic review of the evidence.)</i>	Weak for
<i>Diagnosis</i>	
3. We recommend the diagnosis of hypertension be determined based on at least two blood pressure readings on two separate patient visits. <i>(Modified from 2004 VA/DoD HTN CPG without an updated systematic review of the evidence.)</i>	Strong for
<i>Measurement Techniques</i>	
4. We recommend that blood pressure be measured with a technique recommended for the measurement of blood pressure in adults using a properly calibrated and validated sphygmomanometer. <i>(Modified from 2004 VA/DoD HTN CPG without an updated systematic review of the evidence.)</i>	Strong for
5. For patients whose diagnosis of hypertension remains uncertain, we recommend offering home blood pressure monitoring to confirm diagnosis prior to beginning pharmacologic treatment. (Two to three times a day for seven consecutive days, disregard the first day and take the average of measurements.)	Strong for
6. For patients whose diagnosis of hypertension remains uncertain, we suggest offering 24 hour ambulatory blood pressure monitoring as an alternative to home blood pressure monitoring to confirm diagnosis prior to beginning pharmacologic treatment.	Weak for
Adherence to Therapy	
7. We suggest offering a multi-modal approach to adherence interventions, which could include telemonitoring, multi-disciplinary group medical appointments, (e.g., shared medical appointments), case management (by pharmacists, nurses, social workers), patient and provider education, behavioral therapy, etc.	Weak for
Lifestyle Modification	
8. We recommend offering lifestyle modification interventions for patients with prehypertension or hypertension based on patient indications and preferences as well as assessment of available local resources. <i>(Modified from 2004 VA/DoD HTN CPG)</i>	Strong for
<i>Weight Reduction</i>	
9. We recommend discussing healthy weight range and advising overweight or obese hypertensive patients to reduce their body mass index to below 25. <i>(Modified from 2004 VA/DoD HTN CPG)</i>	Strong for
10. If a normal body mass index (<25) cannot be achieved, we suggest advising patients that a weight reduction of at least 10 pounds can achieve a decrease in blood pressure.	Weak for

Recommendation	Strength of Recommendation
<i>Exercise/Physical Activity</i>	
11. We recommend a target for aerobic exercise of 30 to 45 minutes per session, at least four times per week. <i>(Modified from 2004 VA/DoD HTN CPG)</i>	Strong for
12. We suggest the use of a self-monitoring device (e.g., pedometer, mobile apps, etc.) to increase adherence to physical activity.	Weak for
<i>Mind-body/Alternative Therapies</i>	
13. For patients interested in complementary and alternative medicine, we suggest considering mind-body therapies such as transcendental meditation or yoga.	Weak for
14. We suggest not offering Tai Chi for the treatment of hypertension as there is a moderate body of evidence that shows this intervention does not reduce blood pressure.	Weak against
<i>Dietary Modification</i>	
15. We recommend a dietician-led Dietary Approaches to Stop Hypertension (DASH) Diet for the treatment and/or prevention of hypertension for patients with hypertension and/or interested patients with prehypertension and other cardiovascular risk factors. <i>(Modified from 2004 VA/DoD HTN CPG)</i>	Strong for
16. In patients with additional cardiovascular risk factors, such as dyslipidemia, we suggest considering a dietician-led Mediterranean Diet as an alternative to the DASH Diet.	Weak for
17. We recommend against the use of soy protein supplements for the treatment of hypertension.	Strong against
<i>Sodium Reduction</i>	
18. In patients with hypertension or prehypertension, we recommend that sodium intake be limited to no more than 2300mg/day (100mmol/day), with referral to a dietician or other support as appropriate. <i>(Modified from 2004 VA/DoD HTN CPG)</i>	Strong for
<i>Alcohol Reduction</i>	
19. We recommend advising hypertensive and prehypertensive patients to limit alcohol intake to no more than 1 oz per day for men or 0.5 oz of alcohol per day for women. (This is approximately 2 drinks/day in men and 1 drink/day in women, where a drink is 1.5 oz 80-proof liquor, 12 oz beer, or 5 oz wine [all 14g]). <i>(Modified from 2004 VA/DoD HTN CPG)</i>	Strong for
Pharmacological Therapy	
<i>Initiation of Pharmacotherapy</i>	
20. We recommend offering pharmacologic treatment for hypertensive patients 60 years and older with a systolic blood pressure ≥ 160 mmHg.	Strong for
21. We suggest considering pharmacologic treatment using a shared decision-making model for hypertensive patients 60 years and older with systolic blood pressure <160 mmHg.	Weak for
22. We suggest offering pharmacologic treatment to patients with a history of cerebrovascular disease (stroke, transient ischemic attack, or asymptomatic carotid artery disease) and a systolic blood pressure ≥ 140 mmHg.	Weak for
23. We suggest pharmacologic treatment for hypertensive patients younger than 60 with a systolic blood pressure ≥ 160 mmHg, regardless of diastolic blood pressure.	Weak for

Recommendation	Strength of Recommendation
24. We recommend offering pharmacologic treatment for patients 30 years and older with a diastolic blood pressure ≥ 90 mmHg.	Strong for
25. We suggest offering pharmacologic treatment for patients age 18 to 29 with a diastolic blood pressure ≥ 90 mmHg.	Weak for
<i>Blood Pressure Goals</i>	
26. For patients 60 years and over, we recommend treating to a systolic blood pressure goal of <150 mmHg.	Strong for
27. For patients below 60 years of age, we suggest treating to a systolic blood pressure goal of <150 mmHg.	Weak for
28. We recommend treating to a diastolic blood pressure goal <90 mmHg in patients 30 years and older.	Strong for
29. We suggest treating to a diastolic blood pressure goal <90 mmHg in patients age 18 to 29.	Weak for
30. For patients with diabetes (all age groups), we recommend treating to a systolic blood pressure goal of <150 mmHg.	Strong for
31. For patients with diabetes (all age groups) who tolerate antihypertensive drugs, we suggest treating to a systolic blood pressure goal of <140 mmHg.	Weak for
32. For patients with diabetes, we recommend treating to a diastolic blood pressure goal <85 mmHg.	Strong for
<i>Hypertension Control and Follow-up</i>	
33. We suggest that patients be seen within one month of initiation of lifestyle or pharmacological therapy to determine adequacy of hypertension control, degree of patient adherence, and presence of adverse effects. <i>(Modified from 2004 VA/DoD HTN CPG without an updated systematic review of the evidence.)</i>	Weak for
34. Once the patient's blood pressure is controlled, we suggest follow-up at least annually or more frequently as indicated, depending on patient preference. <i>(Modified from 2004 VA/DoD HTN CPG without an updated systematic review of the evidence.)</i>	Weak for
<i>Monotherapy or Combination Therapy</i>	
35. We suggest taking into consideration the patient's baseline blood pressure and presence of comorbidities, when deciding on either monotherapy or combination therapy (two drugs) when initiating drug therapy. <i>(Modified from 2004 VA/DoD HTN CPG without an updated systematic review of the evidence.)</i>	Weak for
36. We suggest initiating combination therapy for patients with a baseline systolic blood pressure of >20 mmHg or diastolic blood pressure of >10 mmHg above the patient's goal. <i>(Modified from 2004 VA/DoD HTN CPG without an updated systematic review of the evidence.)</i>	Weak for
<i>First Line Therapy</i>	
37. We recommend the use of thiazide-type diuretics for the treatment of hypertension.	Strong for
38. We suggest the use of thiazide-type diuretics at recommended treatment doses as first line therapy for drug treatment of hypertension either as monotherapy or in combination with other agents. <i>(Modified from 2004 VA/DoD HTN CPG)</i>	Weak for
39. To initiate treatment of hypertension with a thiazide-type diuretic, we suggest the use of chlorthalidone or indapamide over hydrochlorothiazide.	Weak for

Recommendation	Strength of Recommendation
40. We do not suggest switching from hydrochlorothiazide to chlorthalidone or indapamide if the patient is adequately controlled on and tolerating hydrochlorothiazide.	Weak against
41. We suggest considering a switch from hydrochlorothiazide to chlorthalidone for patients whose hypertension is inadequately controlled on 50mg/day of hydrochlorothiazide.	Weak for
42. We recommend a dosage of 12.5-25mg/day of chlorthalidone, 25-50mg/day of hydrochlorothiazide, or a dosage of 2.5mg/day immediate-release or 1.5-2.5mg/day sustained-release (not currently available in the US) of indapamide.	Strong for
<i>Alternative or Supplementary Therapies</i>	
43. We recommend using the following as alternative therapies for patients who cannot tolerate thiazide-type diuretics, as supplementary therapies for patients who do not reach their hypertensive goals, or for those starting on combination therapy: <ul style="list-style-type: none"> a. Angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers (but not together) b. Long-acting dihydropyridine calcium channel blockers <i>(Modified from 2004 VA/DoD HTN CPG)</i>	Strong for
44. We recommend against the use of more than one of the following three drug classes together in the same patient: angiotensin-converting-enzyme inhibitors, angiotensin II receptor blockers, or direct renin inhibitors.	Strong against
45. We recommend additional therapy in refractory hypertension (for those who do not tolerate or are not adequately controlled with triple therapy [i.e., thiazide-type diuretics, ACEI or ARB, and CCBs] described in Recommendation 43) or as supplementary therapy in some clinical indications. Drug classes for consideration can include (not in priority order): <ul style="list-style-type: none"> a. Aldosterone/mineralocorticoid receptor antagonists (e.g., spironolactone, eplerenone) b. Other potassium-sparing diuretic (i.e., amiloride) c. Alpha adrenergic blockers d. Beta adrenergic blockers e. Non-dihydropyridine calcium channel blockers f. Combined alpha-beta adrenergic blockers g. Peripherally acting antiadrenergic agents (reserpine, pending availability) h. Direct acting vasodilators (e.g., hydralazine, minoxidil) i. Centrally acting antiadrenergic drugs (e.g., clonidine, methyldopa) 	Strong for
46. We recommend against the use of alpha-adrenergic blockers as monotherapy, but this class of agents may be used as supplemental therapy or if warranted by comorbid conditions (e.g., symptomatic prostatic hypertrophy). <i>(Modified from 2004 VA/DoD HTN CPG)</i>	Strong against
<i>Specific Populations</i>	
47. In patients with hypertension and chronic kidney disease (reduced kidney function with albuminuria), we recommend treatment with an angiotensin-converting-enzyme inhibitor, or angiotensin II receptor blocker for improving	Strong for

Recommendation	Strength of Recommendation
kidney outcomes. (Modified from 2004 VA/DoD HTN CPG)	
48. In African American patients with hypertension, we recommend against using an angiotensin-converting-enzyme inhibitor or angiotensin II receptor blocker as monotherapy.	Strong against
49. In African American patients with hypertension and stage 1-3 chronic kidney disease, we suggest a combination of a thiazide-type diuretic (for cardiovascular protection) with either an angiotensin-converting-enzyme inhibitor or angiotensin II receptor blocker (for renal protection).	Weak for

Table 3. Blood Pressure Thresholds to Initiate Pharmacologic Treatment and Treatment Goals by Patient Category and Age

Patient Age		Blood Pressure (mmHg) ^a	Category of Patient		
			General Population	Diabetic Population	History of cerebrovascular disease
18-29 years	Initiate	SBP	≥160 (Suggested)	≥160 (Suggested) ^b	≥140 (Suggested)
		DBP	≥90 (Suggested)	≥90 (Suggested) ^b	≥90 (Suggested) ^b
	Goals	SBP	<150 (Suggested)	<150 (Recommended)	<150 (Suggested) ^b
		DBP	<90 (Suggested)	<85 (Recommended)	<90 (Suggested) ^b
30-59 years	Initiate	SBP	≥160 (Suggested)	≥160 (Suggested) ^b	≥140 (Suggested)
		DBP	≥90 (Recommended)	≥90 (Recommended) ^b	≥90 (Recommended) ^b
	Goals	SBP	<150 (Suggested)	<150 (Recommended)	<150 (Suggested) ^b
		DBP	<90 (Recommended)	<85 (Recommended)	<90 (Recommended) ^b
>60 years	Initiate	SBP	≥160 (Recommended)	≥160 (Recommended) ^b	≥140 (Suggested)
		DBP	≥90 (Recommended)	≥90 (Recommended) ^b	≥90 (Recommended) ^b
	Goals	SBP	<150 (Recommended)	<150 (Recommended)	<150 (Recommended) ^b
		DBP	<90 (Recommended)	<85 (Recommended)	<90 (Recommended) ^b

^a Initiate pharmacologic treatment at SBP OR DBP threshold; once pharmacologic treatment is initiated, treat to SBP AND DBP goals.

^b Evidence was not reviewed which indicated the blood pressure value should be different from the general population.

Table 4. Recommended Dosage for Selected Hypertension Drug Therapy

Drug^a	Usual Dose Range	Comments^h
Thiazide-type Diuretics		
Chlorthalidone ^b	12.5-25 mg daily	May cause hyperuricemia/gout. Monitor K+ levels. May cause photosensitivity (rare).
HCTZ ^b	12.5-50 mg daily ^f	
Indapamide	IR: 2.5 mg daily SR ^g : 1.25 – 2.5 mg daily	
Angiotensin-Converting Enzyme Inhibitors		
Benazepril	10-40 mg/day (daily or divided bid)	When pregnancy is detected, discontinue as soon as possible, due to potential for fetal and neonatal morbidity and death. Patients of child-bearing potential should also be educated about the risks. Do not use if history of angioedema. Avoid concomitant use of ACEI with ARB or direct renin inhibitor due to increased risk of hypotension, syncope, increased K+, and changes in renal function (See recommendation #44). Monitor K+ and kidney function; use caution if combined with, K+ sparing diuretic, or K+ supplement. Consider interruption or discontinuation in patients who develop clinically significant decline in kidney function after initiation of therapy, until further work-up, as indicated (e.g., renal artery stenosis).
Enalapril	5-40 mg/day (daily or divided bid)	
Fosinopril	10-40 mg daily	
Lisinopril ^b	10-40 mg daily	
Ramipril ^{b,c}	2.5-20 mg/day (daily or divided bid) (10 mg daily for CV risk prevention)	
Angiotensin II Receptor Blockers		
Azilsartan ^c	40-80 mg daily	When pregnancy is detected, discontinue as soon as possible. Drugs that act directly on the renin angiotensin system can cause injury and death to the developing fetus. Patients of child-bearing potential should also be educated about the risks. Avoid concomitant use of ACEI with angiotensin II receptor blocker or direct renin inhibitor due to increased risk of hypotension, syncope, increased K+, and changes in renal function (See recommendation #44). Monitor K+ and kidney function; use
Candesartan ^c	8-32 mg daily	
Eprosartan ^c	400-800 mg/daily (daily or divided bid)	
Irbesartan ^c	150-300 mg daily	
Losartan ^b	25-100 mg/day (daily or divided bid)	
Olmesartan ^c	20-40 mg daily	
Telmisartan ^c	20-80 mg daily	
Valsartan ^{b,d}	80-320 mg daily	

		caution if combined with, K ⁺ sparing diuretic, or K ⁺ supplement.
		Consider interruption or discontinuation in patients who develop clinically significant decline in kidney function after initiation of therapy, until further work-up, as indicated (e.g., renal artery stenosis).
Long-Acting Dihydropyridine Calcium Channel Blockers		
Amlodipine ^b	2.5-10 mg daily	Monitor adverse effects (DHP CCBs may cause ankle edema, dizziness, flushing, headache).
Felodipine	2.5-10 mg daily	
Nifedipine SR ^b	30-120 mg daily	
		Use with caution in patients with hepatic or renal dysfunction.
Aldosterone/mineralocorticoid Receptor Antagonists		
Eplerenone ^c	50-100 mg/day (daily or divided bid)	Avoid use if hyperkalemia or severe kidney dysfunction.
Spirolactone ^b	25-50 mg/daily	
		Monitor K ⁺ and kidney function; consider risk vs. benefit if combined with ACEI, ARB, K ⁺ sparing diuretic, or K ⁺ supplement.
		Higher risk of gynecomastia with spironolactone than eplerenone.
Other Potassium-Sparing Diuretics		
Amiloride ^c	5-10 mg daily	Avoid use if hyperkalemia or severe kidney dysfunction. Helpful in reducing hypokalemia caused by thiazide diuretics.
Alpha-Adrenergic Blockers		
Doxazosin	1-16 mg daily	Initiate at low doses (1 mg).
Prazosin	2-20 mg/day (divided bid or tid)	Administer 1 st dose at bedtime to avoid syncope.
Terazosin ^b	1-20 mg daily	
		Avoid use as monotherapy (See recommendation #46).
Beta-Adrenergic Blockers		
<i>Noncardioselective</i>		Discontinue with slow taper over one week.
Propranolol	IR: 80-160 mg/day (divided bid) SR: 80-160 mg daily	Avoid combination with non-DHP CCB due to increased risk of bradycardia.
<i>Cardioselective</i>		As doses increase, cardioselectivity decreases.
Atenolol ^b	25-100 mg daily (adjust dose in CKD)	
Metoprolol tartrate ^b	IR: 50-300 mg/day (daily or divided bid)	Beta-blockers should be used cautiously in
Metoprolol	SR: 25-200 mg/day	

succinate (XL) ^{b,d}		asthma.
Long-Acting Non-Dihydropyridine Calcium Channel Blockers		
Verapamil SR ^b	120-480 mg divided daily-bid	Verapamil may cause constipation; verapamil is contraindicated in AV node dysfunction (2nd or 3rd degree heart block), systolic HF and ↓ LV function.
Diltiazem SR ^b	120-540 mg daily	Diltiazem may ↓ sinus rate and cause heart block. Use CCBs with caution in patients with liver or kidney dysfunction.
Combined Alpha-beta adrenergic blockers		
Carvedilol	IR ^b : 12.5-50 mg/day (divided bid) SR ^c : 20-80 mg/day	Precautions for beta-blockers apply.
Labetalol ^c	200-800 mg/day (divided bid)	
Peripherally Acting Adrenergic Agents		
Reserpine ^e	0.1-0.25 mg daily	Monitor for sedation, and nasal congestion.
Direct Acting Vasodilators		
Minoxidil	2.5-100 mg/day (daily or divided bid)	Direct acting vasodilators often need concomitant use of diuretic and beta-blocker to reduce edema and reflex tachycardia. Monitor for hypertrichosis and pericardial effusions with minoxidil. Monitor for headache and SLE (dose-related) with hydralazine.
Hydralazine ^b	50-200 mg/day (divided bid)	
Centrally Acting Antiadrenergic Drugs		
Clonidine Tablet ^b	0.1-0.8 mg/day (divided bid)	Monitor for somnolence and dry mouth. Taper dose to discontinue.
Clonidine Patch	0.1-0.3 mg patch weekly	Clonidine patches may be useful in select patients.
Methyldopa	500-2,000 mg/day (divided bid)	

ACEI=angiotensin-converting enzyme inhibitor; ARB=angiotensin II receptor blocker; AV=atrioventricular; bid=twice daily; CCB=calcium channel blockers; CKD=chronic kidney disease; CV=cardiovascular; HCTZ=hydrochlorothiazide; HF=heart failure; IR=immediate-release; K+=potassium; LV=left ventricular; SLE=systemic lupus erythematosus; SR=sustained-release

^a Partial list; refer to <http://www.pbm.va.gov/nationalformulary.asp> for items available on the VA National Formulary (VANF) and refer to http://pec.ha.osd.mil/formulary_search.php?submenuheader=1 for items available on the DoD Uniform Formulary. All drugs listed are on the DoD Uniform Formulary.

^b DoD Basic Core Formulary (BCF) item.

^c Item not on VANF

^d Restricted to patients with chronic heart failure in VA.

^e Reserpine not currently available in the U.S. due to changes in requirements for raw materials (re-verified 10/15/2014; next available supply estimated March 2015). Refer to FDA Drug Shortages for current information.

^f 12.5 mg may be considered as an initial dose with titration recommended to 25 to 50mg daily; refer to Recommendation 42 and associated discussion for further information.

^g Indapamide SR not currently available in the US.

^h

For complete drug information, review the manufacturer's prescribing information.

References

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2013 update: A report from the American Heart Association. *Circulation*. Jan 1 2013;127(1):e6-e245.
2. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: The national health and nutrition examination survey, 2001 to 2010. *Circulation*. Oct 23 2012;126(17):2105-2114.
3. Smoley BA, Smith NL, Runkle GP. Hypertension in a population of active duty Service Members. *J Am Board Fam Med*. Nov-Dec 2008;21(6):504-511.
4. VA Health Services Research & Development. *Spotlight: Hypertension and stroke*. http://www.hsrd.research.va.gov/news/feature/hypertension_stroke.cfm. Updated June 2011. Accessed October 27, 2014.
5. Fletcher RD, Amdur RL, Kolodner R, et al. Blood pressure control among US veterans: A large multiyear analysis of blood pressure data from the Veterans Administration health data repository. *Circulation*. May 22 2012;125(20):2462-2468.
6. Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: The significance and presentation of recommendations. *J Clin Epidemiol*. Jul 2013;66(7):719-725.